Genome Editing Technology

Selected news for the healthcare topic - Genome Editing Technology, collected since 10/2017. Recent stories appear in ZDNet and boingboing.net. This healthcare topic shares news with CRISPR, Precision BioSciences, LogicBio Therapeutics and many others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
3/3/2021 ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical financialbuzz.com ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka). The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner ...
3/2/2021 Scientists Use Lipid Nanoparticles to Precisely Target Gene Editing to the Liver tufts.edu EmailThe genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively, and specifically targeted to the gene, tissue and organ that needs treatment. Scientists at Tufts University and the Broad Institute of Harvard and MIT have developed unique nanoparticles comprised of lipids -- fat ...
3/2/2021 Unique nanoparticles can package and deliver gene-editing machinery to the liver news-medical.net The genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively, and specifically targeted to the gene, tissue and organ that needs treatment. Scientists at Tufts University and the Broad Institute of Harvard and MIT have developed unique nanoparticles comprised of lipids -- fat molecules ...
3/1/2021 Scientists use lipid nanoparticles to precisely target gene editing to the liver sciencedaily.com ... specific tissues and organs, demonstrating the treatment of high cholesterol by targeting genes in the liver of mice, reducing cholesterol for over 3 months (and potentially more) with one treatment. Share: FULL STORY The genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively ...
3/1/2021 Scientists use lipid nanoparticles to precisely target gene editing to the liver Phys Org ... levels of LDL "bad" cholesterol in the blood. Together with earlier studies demonstrating delivery to the brain or T cells suggest a future possibility of highly targeted gene editing therapies. Credit: Tufts UniversityThe genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively ...
3/1/2021 Using lipid nanoparticles to precisely target gene editing to the liver nanowerk.com Mar 01, 2021 Using lipid nanoparticles to precisely target gene editing to the liver ( Nanowerk News ) The genome editing technology CRISPR has emerged as a powerful new tool that can change the way we treat disease. The challenge when altering the genetics of our cells, however, is how to do it safely, effectively, and specifically targeted to the gene, tissue and organ that needs treatment. Scientists at Tufts University and ...
2/28/2021 J.P. Morgan Downgrades Editas Medicine (EDIT) to Sell analystratings.com ... Äôs market cap is currently $2.76B and has a P/E ratio of -28.70. The company has a Price to Book ratio of 7.08.Editas Medicine, Inc. engages in the development and commercialization of genome editing technology . Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and ...
2/26/2021 Raymond James Initiates a Hold Rating on Editas Medicine (EDIT) markets.co ... Äôs market cap is currently $2.81B and has a P/E ratio of -28.40. The company has a Price to Book ratio of 7.00.Editas Medicine, Inc. engages in the development and commercialization of genome editing technology . Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and ...
2/9/2021 Hoxton Farms raises ÂŁ2.7M seed to produce animal fat without animals TechCrunch ... started the company with longtime school friend Dr Max Jamilly, who has two degrees in biotechnology and a PhD in synthetic biology (the pair met at pre-school). “I spent my PhD using a genome editing technology called CRISPR to discover better treatments for children’s leukaemia,” says Jamilly. “Along the way, I learnt how to grow complex cells at scale — a fundamental part of the scientific challenge ...
2/9/2021 Hoxton Farms raises £2.7M seed to produce animal fat without animals Yahoo News ... started the company with longtime school friend Dr Max Jamilly, who has two degrees in biotechnology and a PhD in synthetic biology (the pair met at pre-school). “I spent my PhD using a genome editing technology called CRISPR to discover better treatments for children's leukaemia,” says Jamilly. “Along the way, I learnt how to grow complex cells at scale -- a fundamental part of the scientific challenge that we ...
2/9/2021 Hoxton Farms raises £2.7M seed to produce animal fat without animals google.com ... started the company with longtime school friend Dr Max Jamilly, who has two degrees in biotechnology and a PhD in synthetic biology (the pair met at pre-school). “I spent my PhD using a genome editing technology called CRISPR to discover better treatments for children’s leukaemia,” says Jamilly. “Along the way, I learnt how to grow complex cells at scale — a fundamental part of the scientific challenge ...
2/9/2021 Hoxton Farms raises £2.7M seed to produce animal fat without animals dailymagazine.news ... started the company with longtime school friend Dr Max Jamilly, who has two degrees in biotechnology and a PhD in synthetic biology (the pair met at pre-school). "I spent my PhD using a genome editing technology called CRISPR to discover better treatments for children's leukaemia," says Jamilly. "Along the way, I learnt how to grow complex cells at scale -- a fundamental part of the scientific challenge that we face ...
11/16/2020 ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio's Portfolio of Innovative Cell and Gene Therapy Companies BioSpace ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy CompaniesPublished: Nov 16, 2020 Nov. 16, 2020 12:30 UTC - Highly innovative genome editing technology platform accelerates and broadens ElevateBio’s cell and gene therapy enabling technologies - LifeEDIT Therapeutics to develop its own pipeline of potentially life-transforming therapeutics - LifeEDIT Therapeutics to leverage its novel gene editing platform with strategic partners including ElevateBio portfolio ...
10/10/2020 Australian and New Zealand scientists use AI to predict heart disease risk ZDNet Scribe Therapeutics Inc. co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry along with collaborator Emmanuelle Charpentier, Ph.D., for their discovery of CRISPR, the genome editing technology that has transformed modern science and biomedicine. The two scientists are the first women to jointly win a Nobel Prize.Doudna published her initial work on the CRISPR-Cas9 system and its potential for rewriting the DNA of ...
10/1/2020 Call for a Citizens’ Assembly to Help Govern Genome Editing genengnews.com If you like the idea of juries weighing evidence and delivering verdicts, you might also like the idea of global citizens’ assemblies deliberating over genome editing technology . Both juries and citizen’s assemblies reflect the same democratic impulse: the desire to expand the circle of decision-makers to include people from all walks of life, not just the highly credentialed. Everyone, the highly credentialed and the rest of us, will live ...
9/29/2020 malvern-online.com Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees. Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and ...
9/29/2020 Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees Benzinga Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees. Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and ...
9/29/2020 Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees firstwordpharma.com Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees (Ref: Business Wire) Print HANGZHOU, China--( BUSINESS WIRE )-- Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific ...
9/29/2020 Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees BioSpace HANGZHOU, China--( BUSINESS WIRE )-- Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees. Qihan was founded in 2018 to develop novel cell and organ therapies using ...
9/29/2020 Qihan Biotech Expands Scientific Advisory Board and Establishes Scientific Advisory Committees financialbuzz.com Qihan Biotech, a leader in applying genome editing technology to cell therapies and organ transplantation, today announced the expansion of its Scientific Advisory Board to include a total of 12 world-renowned experts in synthetic biology, regenerative medicine, transplantation immunology and cell therapy, as well as the formation of several Scientific Advisory Committees.Qihan was founded in 2018 to develop novel cell and organ therapies using multiplexable genome editing and ...